| Status: Recommended with restrictions | |||
Aviptadil / phentolamine (Invicorp®) is recommended as an option for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology. Aviptadil / phentolamine (Invicorp®) is restricted to use in people with erectile dysfunction that has not responded to oral PDE5 inhibitor therapy. Aviptadil / phentolamine (Invicorp®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | aviptadil / phentolamine mesilate (Invicorp®) | ||
| Formulation | 25 micrograms / 2 mg solution for injection | ||
| Reference number | 3435 | ||
| Indication | Symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology |
||
| Company | Evolan Pharma AB | ||
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | ||
| Submission type | Resubmission | ||
| Status | Recommended with restrictions | ||
| Advice number | 1117 | ||
| NMG meeting date | 03/05/2017 | ||
| AWMSG meeting date | 21/06/2017 | ||
| Date of issue | 12/07/2017 | ||
| Date of last review | September 2020 | ||